NCT01833130 - Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Chronic Migraine

Interventions

BIOLOGICAL

OnabotulinumtoxinA

OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.

DRUG

Normal saline (placebo)

Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.

Trial Locations (1)

Unknown

San Francisco